{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:38:24Z","timestamp":1787701104103,"version":"build-2784847793"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0054518, NNF19OC0055462"],"award-info":[{"award-number":["NNF19OC0054518, NNF19OC0055462"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009459","name":"Hvidovre Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chronic hepatitis C virus (HCV) infection drives T cells into a dysfunctional state due to persistent antigen exposure. This state persists despite viral clearance with previously used interferon-based treatments. Treatment exclusively with direct-acting antivirals (DAAs), introduced in 2014, has revolutionised HCV treatment with cure rates exceeding 95%. This systematic review investigates whether HCV cure by DAA treatment restores the functional capacity of different exhausted T cell subsets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched the databases PubMed and Embase on June 26<jats:sup>th<\/jats:sup>, 2024, for studies assessing T cell exhaustion post-cure by DAA treatment. Eligibility criteria included interferon-free DAA treatment of adult patients with chronic HCV infection, with no co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV). Studies meeting all inclusion and no exclusion criteria were eligible for full-text screening, and only studies presenting original data were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The search identified a total of 448 articles, with 35 articles eligible for full-text screening. Among these, 26 met the inclusion criteria and were included in this systematic review. A total of 919 individuals with chronic HCV infection were included. Following HCV cure, most T cell subsets showed only partial restoration of function. Notably, advanced stages of fibrosis were associated with sustained exhaustion across multiple T cell subsets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This systematic review found that exhausted T cell subsets are only partially restored after HCV cure by DAA treatment. Severe fibrosis, which can be considered a proxy for the duration of infection, appears to impede the reversal of the immune dysfunction. Further studies are warranted to better understand the influence of potential confounders such as age, sex, fibrosis stage, and duration of infection on the restoration of immune function to gain essential insights for future research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42024540474.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1546915","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:31:33Z","timestamp":1756704693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cure of chronic hepatitis C virus infection after DAA treatment only partially restores the functional capacity of exhausted T cell subsets: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"\u00c1sa Didriksen","family":"Apol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"S\u00f8lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"B1","unstructured":"Global hepatitis report 2024 Action for access in low- and middle-income countries\n          \n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis c virus infection: A systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv220","article-title":"Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study","volume":"212","author":"Sacks-Davis","year":"2015","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"J Viral Hepat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1467963","article-title":"Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation","volume":"53","author":"S\u00f8lund","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4030027","article-title":"Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection","volume":"4","author":"Swadling","year":"2016","journal-title":"Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"105424","DOI":"10.1016\/j.ebiom.2024.105424","article-title":"Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030","volume":"110","author":"Hasso-Agopsowicz","year":"2024","journal-title":"EBioMedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v12080799","article-title":"Reversal of t cell exhaustion in chronic HCV infection","volume":"12","author":"Osuch","year":"2020","journal-title":"Viruses"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10050991","article-title":"CD8+ t cell responses during HCV infection and HCC","volume":"10","author":"Hofmann","year":"2021","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2023","journal-title":"Nature Immunology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nature Reviews Immunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B15","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.09.022","article-title":"T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine","volume":"74","author":"Thimme","year":"2021","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.025","article-title":"Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses","volume":"71","author":"Aregay","year":"2019","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15050","article-title":"TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation","volume":"8","author":"Wieland","year":"2017","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00817-w","article-title":"Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection","volume":"22","author":"Hensel","year":"2021","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00979-1","article-title":"After cure of chronic infection in humans","volume":"22","author":"Yates","year":"2021","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz223","article-title":"Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection","volume":"6","author":"Stevenson","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-73137-6","article-title":"Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C","volume":"10","author":"Osuch","year":"2020","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12702","article-title":"Augmentation of hepatitis C virus-specific immunity and sustained virologic response","volume":"24","author":"Shrivastava","year":"2017","journal-title":"J Viral Hepat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13370","article-title":"Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8+ T cells after direct-acting antiviral therapies","volume":"27","author":"Perpi\u00f1\u00e1n","year":"2020","journal-title":"J Viral Hepat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00982-6","article-title":"Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory","volume":"22","author":"Tonnerre","year":"2021","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0254243","article-title":"Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy","volume":"16","author":"Llorens-Revull","year":"2021","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41467-019-14137-7","article-title":"Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection","volume":"11","author":"Barili","year":"2020","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor article bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8 + T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fviro.2023.1198361","article-title":"Chronic HCV infection promotes cytotoxicity in antigen-specific CD8+ T cells regardless of virus specificity","volume":"3","author":"Maretti-Mira","year":"2023","journal-title":"Front Virol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.0192","article-title":"Direct-acting antiviral treatment of hcv infection does not resolve the dysfunction of circulating CD8+ T-cells in advanced liver disease","volume":"10","author":"Vranjkovic","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00618-3","article-title":"Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C","volume":"20","author":"Szereday","year":"2020","journal-title":"Clin Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-05657-5","article-title":"Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection","volume":"20","author":"Orr","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12465","article-title":"Memory re-differentiation and reduced lymphocyte activation in chronic HCV -infected patients receiving direct-acting antivirals","volume":"22","author":"Burchill","year":"2015","journal-title":"J Viral Hepat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10111488","article-title":"Short-and long-term immunological responses in chronic HCV\/HIV co-infected compared to HCV mono-infected patients after DAA therapy","volume":"10","author":"Farcomeni","year":"2021","journal-title":"Pathogens"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162034","article-title":"Endotoxemia associated with liver disease correlates with systemic inflammation and T cell exhaustion in hepatitis C virus infection","volume":"12","author":"Shive","year":"2023","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32349","article-title":"Innate-like bystander-activated CD38+HLA-DR+CD8+T cells play a pathogenic role in patients with chronic hepatitis C","volume":"76","author":"Huang","year":"2022","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1172\/JCI129642","article-title":"Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination","volume":"130","author":"Smits","year":"2020","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-77020-2","article-title":"Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus","volume":"10","author":"Khanam","year":"2020","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.007","article-title":"Human liver infiltrating gamma delta T cells are composed of clonally expanded circulating and tissue-resident populations","volume":"69","author":"Hunter","year":"2018","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13121","article-title":"Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure","volume":"26","author":"Ghosh","year":"2019","journal-title":"J Viral Hepat"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0444-8","article-title":"The biology and functional importance of MAIT cells","volume":"20","author":"Godfrey","year":"2019","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646447","article-title":"Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy","volume":"46","author":"Hengst","year":"2016","journal-title":"Eur J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12101446","article-title":"Double positive CD4+CD8+ (DP) T-cells display distinct exhaustion phenotype in chronic hepatitis C","volume":"12","author":"Kochanowicz","year":"2023","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13464","article-title":"NK cell exhaustion, B-cell exhaustion and T-cell exhaustion \u2014 \u00ad the differences and similarities","volume":"166","author":"Roe","year":"2022","journal-title":"Immunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.31273","article-title":"Adaptive natural killer cell functional recovery in hepatitis C virus cured patients","volume":"73","author":"Mele","year":"2021","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD 56 bright natural killer (NK) cells : an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Br Soc Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27254","article-title":"Immune tolerance in liver disease","volume":"60","author":"Crispe","year":"2014","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01094-10","article-title":"Comparison of Immune Restoration in Early versus Late Alpha Interferon Therapy against Hepatitis C Virus","volume":"84","author":"Abdel-hakeem","year":"2010","journal-title":"J Virol"},{"key":"B51","article-title":"Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection","volume":"45","author":"Penna","year":"","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00975-5","article-title":"Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation","volume":"22","author":"Abdel-Hakeem","year":"2021","journal-title":"Nat Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102011","article-title":"The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B\/C, HIV): A review of the available evidence","volume":"86","author":"Tapia Rico","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and ef fi cacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer","volume":"5","author":"Pu","year":"2020","journal-title":"Medicine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf2226","article-title":"Toward a vaccine against hepatitis C virus","volume":"380","author":"Offersgaard","year":"2023","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/v13050833","article-title":"From structural studies to hcv vaccine design","volume":"13","author":"Yechezkel","year":"2021","journal-title":"Viruses"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit301","article-title":"Hepatitis C virus reinfection following treatment among people who use drugs","volume":"57","author":"Grady","year":"2013","journal-title":"Clinical Infectious Diseases"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1546915\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:31:36Z","timestamp":1756704696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1546915\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2025.1546915"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1546915","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"1546915"}}